# Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC

> **NCT06078384** · PHASE2 · RECRUITING · sponsor: **UNICANCER** · enrollment: 354 (estimated)

## Conditions studied

- Triple-negative Breast Cancer

## Interventions

- **DRUG:** Pembrolizumab 25 mg/ml
- **DRUG:** Paclitaxel injection

## Key facts

- **NCT ID:** NCT06078384
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-27
- **Primary completion:** 2032-01-01
- **Final completion:** 2032-01-01
- **Target enrollment:** 354 (ESTIMATED)
- **Last updated:** 2025-11-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06078384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06078384, "Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06078384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*